argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 dec 2014 - 07:04
Statutaire naam
argenx SE
Titel
arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire
Bericht
Shire to take one or more collaborative product candidates into preclinical development
11 December 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates created out of a 2012 therapeutic antibody alliance between the two companies. As a result of the exercise, arGEN-X will receive a milestone payment from Shire.
Datum laatste update: 11 januari 2026